Abstract:
The objective of present research work was to formulate nanoparticles of lansoprazole using Eudragit RLPO® (ERLPO) as carrier to protect it from acidic pH and to improve its solubility. The nanoparticles were prepared by the solvent displacement method (nanoprecipitation). Lansoprazole is a benzimidazole derivative, which is used as a representative proton pump inhibitor. The compatibility of lansoprazole and Eudragit RLPO was evaluated by the Fourier transform infrared spectroscopy (FTIR) and Differential Scanning Calorimetry (DSC). The formulated nanoparticles were evaluated by Powder X Ray Diffractometry (PXRD) and Scanning Electron Microscopy (SEM). DSC results showed that there is not any drug- excipient interaction. Saturation solubility and dissolution studies indicated that dissolution rate was remarkably increased in lyophilized Formulation as compared to drug alone. The in vitro drug release study showed that very less drug was released in the pH 1.2 dissolution medium within 2h whereas 90 % of the drug was released in the pH 6.8. In conclusion Eudragit RLPO can be suitably utilized to increase the solubility and acid resistance of lansoprazole.

Keywords: Lansoprazole, Nanoparticles, Eudragit RLPO, Solvent Displacement, Saturation Solubility.